These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22451244)

  • 21. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
    Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Neuvonen M; Neuvonen PJ; Olkkola KT
    Drugs Aging; 2011 Jan; 28(1):41-50. PubMed ID: 21174486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions.
    Leibowitz MT; Zamora CA; Brzeczko AW; Stark JG
    Am J Ther; 2014; 21(2):99-105. PubMed ID: 22357166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal interaction between gatifloxacin and oxycodone.
    Grant EM; Nicolau DR; Nightingale C; Quintiliani R
    J Clin Pharmacol; 2002 Aug; 42(8):928-32. PubMed ID: 12162476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study.
    Webster LR; Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Jul; 36(7):1730-1740. PubMed ID: 31065992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine.
    Kokki M; Heikkinen M; Välitalo P; Hautajärvi H; Hokkanen J; Pitkänen H; Sankilampi U; Ranta VP; Kokki H
    Br J Clin Pharmacol; 2017 Apr; 83(4):791-800. PubMed ID: 27780305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
    Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
    J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetics of oral oxycodone in patients after total gastric resection.
    Szałek E; Karbownik A; Murawa D; Połom K; Tezyk A; Gracz J; Grabowski T; Grześkowiak E; Biczysko-Murawa A; Murawa P
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):3126-33. PubMed ID: 25392115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
    Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation.
    Kirvela M; Lindgren L; Seppala T; Olkkola KT
    J Clin Anesth; 1996 Feb; 8(1):13-8. PubMed ID: 8695073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
    Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets.
    Kim JY; Lee SH; Park CW; Rhee YS; Kim DW; Park J; Lee M; Seo JW; Park ES
    Drug Des Devel Ther; 2015; 9():695-706. PubMed ID: 25678774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
    Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
    J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).
    Meske D; Kopecky EA; Passik S; Shram MJ
    J Opioid Manag; 2018; 14(5):359-372. PubMed ID: 30387859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
    Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB
    Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic Bioequivalence Studies of an Extended-Release Oxycodone Hydrochloride Tablet in Healthy Japanese Subjects Under Fasting and Fed Conditions Without an Opioid Antagonist.
    Toyama K; Furuie H; Kuroda K; Ishizuka H
    Drugs R D; 2017 Sep; 17(3):363-370. PubMed ID: 28516342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steady-state bioavailability of controlled-release oxycodone in normal subjects.
    Reder RF; Oshlack B; Miotto JB; Benziger DD; Kaiko RF
    Clin Ther; 1996; 18(1):95-105. PubMed ID: 8851456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of oxycodone after intravenous and subcutaneous administration in Japanese patients with cancer pain.
    Kokubun H; Yoshimoto T; Hojo M; Fukumura K; Matoba M
    J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):338-50. PubMed ID: 25359452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone.
    Ladebo L; Abuhelwa AY; Foster DJR; Kroustrup JP; Pacyk GJ; Kongstad KT; Drewes AM; Christrup LL; Olesen AE
    Basic Clin Pharmacol Toxicol; 2021 Sep; 129(3):232-245. PubMed ID: 34228875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the pharmacokinetics of oxycodone administered in three Percocet formulations.
    Gammaitoni AR; Davis MW
    J Clin Pharmacol; 2002 Feb; 42(2):192-7. PubMed ID: 11831542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics of oxycodone in patients with cancer-related pain.
    Komatsu T; Kokubun H; Suzuki A; Takayanagi R; Yamada Y; Matoba M; Yago K
    J Pain Palliat Care Pharmacother; 2012 Sep; 26(3):220-5. PubMed ID: 22973910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.